{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:16:47Z","timestamp":1772173007098,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1010065","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000}}],"reference-count":82,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","award":["1ZIAHG200323"],"award-info":[{"award-number":["1ZIAHG200323"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>\n                    Mutations to the human kinome are known to play causal roles in cancer. The kinome regulates numerous cell processes including growth, proliferation, differentiation, and apoptosis. In addition to aberrant expression, aberrant alternative splicing of cancer-driver genes is receiving increased attention as it could lead to loss or gain of functional domains, altering a kinase\u2019s downstream impact. The present study quantifies changes in gene expression and isoform ratios in the kinome of metastatic melanoma cells relative to primary tumors. We contrast 538 total kinases and 3,040 known kinase isoforms between 103 primary tumor and 367 metastatic samples from The Cancer Genome Atlas (TCGA). We find strong evidence of differential expression (DE) at the gene level in 123 kinases (23%). Additionally, of the 468 kinases with alternative isoforms, 60 (13%) had significant difference in isoform ratios (DIR). Notably, DE and DIR have little correlation; for instance, although DE highlights enrichment in receptor tyrosine kinases (RTKs), DIR identifies altered splicing in non-receptor tyrosine kinases (nRTKs). Using exon junction mapping, we identify five examples of splicing events favored in metastatic samples. We demonstrate differential apoptosis and protein localization between\n                    <jats:italic>SLK<\/jats:italic>\n                    isoforms in metastatic melanoma. We cluster isoform expression data and identify subgroups that correlate with genomic subtypes and anatomic tumor locations. Notably, distinct DE and DIR patterns separate samples with\n                    <jats:italic>BRAF<\/jats:italic>\n                    hotspot mutations and\n                    <jats:italic>(N\/K\/H)RAS<\/jats:italic>\n                    hotspot mutations, the latter of which lacks effective kinase inhibitor treatments. DE in\n                    <jats:italic>RAS<\/jats:italic>\n                    mutants concentrates in CMGC kinases (a group including cell cycle and splicing regulators) rather than RTKs as in\n                    <jats:italic>BRAF<\/jats:italic>\n                    mutants. Furthermore, isoforms in the\n                    <jats:italic>RAS<\/jats:italic>\n                    kinase subgroup show enrichment for cancer-related processes such as angiogenesis and cell migration. Our results reveal a new approach to therapeutic target identification and demonstrate how different mutational subtypes may respond differently to treatments highlighting possible new driver events in cancer.\n                  <\/jats:p>","DOI":"10.1371\/journal.pcbi.1010065","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T13:42:35Z","timestamp":1652449355000},"page":"e1010065","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Characterization and clustering of kinase isoform expression in metastatic melanoma"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6742-6546","authenticated-orcid":true,"given":"David O.","family":"Holland","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7857-3309","authenticated-orcid":true,"given":"Valer","family":"Gotea","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2327-420X","authenticated-orcid":true,"given":"Kevin","family":"Fedkenheuer","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7854-6255","authenticated-orcid":true,"given":"Sushil K.","family":"Jaiswal","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1545-6863","authenticated-orcid":true,"given":"Catherine","family":"Baugher","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4090-113X","authenticated-orcid":true,"given":"Hua","family":"Tan","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2715-2904","authenticated-orcid":true,"given":"Michael","family":"Fedkenheuer","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1065-019X","authenticated-orcid":true,"given":"Laura","family":"Elnitski","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"issue":"10151","key":"pcbi.1010065.ref001","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"D Schadendorf","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"pcbi.1010065.ref002","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"A Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"pcbi.1010065.ref003","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11060-017-2591-9","article-title":"Metastatic melanoma: prognostic factors and survival in patients with brain metastases","volume":"135","author":"E Frinton","year":"2017","journal-title":"J Neurooncol"},{"issue":"1","key":"pcbi.1010065.ref004","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer","volume":"17","author":"Z Du","year":"2018","journal-title":"Mol Cancer"},{"key":"pcbi.1010065.ref005","first-page":"1","volume-title":"eLS","author":"A Tsintarakis","year":"2017"},{"issue":"11\u201312","key":"pcbi.1010065.ref006","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/1947601913479022","article-title":"Cyclins and cell cycle control in cancer and disease","volume":"3","author":"MC Casimiro","year":"2012","journal-title":"Genes Cancer"},{"issue":"22","key":"pcbi.1010065.ref007","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"AS Dhillon","year":"2007","journal-title":"Oncogene"},{"issue":"4","key":"pcbi.1010065.ref008","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc2823","article-title":"The regulatory crosstalk between kinases and proteases in cancer","volume":"10","author":"C Lopez-Otin","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"pcbi.1010065.ref009","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc.2015.18","article-title":"The kinome \u2019at large\u2019 in cancer","volume":"16","author":"ED Fleuren","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"pcbi.1010065.ref010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targeted cancer therapies: progress, challenges and future directions","volume":"17","author":"KS Bhullar","year":"2018","journal-title":"Mol Cancer"},{"issue":"7","key":"pcbi.1010065.ref011","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic Classification of Cutaneous Melanoma","volume":"161","author":"The Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"issue":"18","key":"pcbi.1010065.ref012","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"DB Johnson","year":"2015","journal-title":"Eur J Cancer"},{"issue":"11","key":"pcbi.1010065.ref013","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1080\/14737140.2017.1374177","article-title":"Binimetinib for the treatment of NRAS-mutant melanoma","volume":"17","author":"P Queirolo","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"issue":"14","key":"pcbi.1010065.ref014","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"JD Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"pcbi.1010065.ref015","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"C Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"pcbi.1010065.ref016","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"C Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"pcbi.1010065.ref017","first-page":"243","article-title":"Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma","volume":"4","author":"R Fisher","year":"2012","journal-title":"Cancer Manag Res"},{"key":"pcbi.1010065.ref018","article-title":"Alternative Splicing in Oncogenic Kinases: From Physiological Functions to Cancer","author":"S Druillennec","year":"2012","journal-title":"J Nucleic Acids"},{"issue":"12","key":"pcbi.1010065.ref019","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/nmeth.2714","article-title":"Assessment of transcript reconstruction methods for RNA-seq","volume":"10","author":"T Steijger","year":"2013","journal-title":"Nat Methods"},{"key":"pcbi.1010065.ref020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"B Li","year":"2011","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"pcbi.1010065.ref021","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nbt.3519","article-title":"Near-optimal probabilistic RNA-seq quantification","volume":"34","author":"NL Bray","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"5","key":"pcbi.1010065.ref022","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.gpb.2015.08.002","article-title":"PacBio Sequencing and Its Applications","volume":"13","author":"A Rhoads","year":"2015","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"5","key":"pcbi.1010065.ref023","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.gpb.2016.05.004","article-title":"Oxford Nanopore MinION Sequencing and Genome Assembly","volume":"14","author":"H Lu","year":"2016","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"pcbi.1010065.ref024","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3389\/fgene.2019.00709","article-title":"Getting the Entire Message: Progress in Isoform Sequencing","volume":"10","author":"SA Hardwick","year":"2019","journal-title":"Front Genet"},{"issue":"7221","key":"pcbi.1010065.ref025","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nature07509","article-title":"Alternative isoform regulation in human tissue transcriptomes","volume":"456","author":"ET Wang","year":"2008","journal-title":"Nature"},{"issue":"5","key":"pcbi.1010065.ref026","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nbt.1621","article-title":"Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation","volume":"28","author":"C Trapnell","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"1","key":"pcbi.1010065.ref027","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/ng.1045","article-title":"Spliceosome mutations in hematopoietic malignancies","volume":"44","author":"CN Hahn","year":"2011","journal-title":"Nat Genet"},{"issue":"2","key":"pcbi.1010065.ref028","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ng.2523","article-title":"Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma","volume":"45","author":"JW Harbour","year":"2013","journal-title":"Nat Genet"},{"issue":"7569","key":"pcbi.1010065.ref029","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature14985","article-title":"The spliceosome is a therapeutic vulnerability in MYC-driven cancer","volume":"525","author":"TY Hsu","year":"2015","journal-title":"Nature"},{"issue":"1","key":"pcbi.1010065.ref030","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.celrep.2018.01.088","article-title":"Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types","volume":"23","author":"M Seiler","year":"2018","journal-title":"Cell Rep"},{"issue":"19","key":"pcbi.1010065.ref031","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/onc.2015.318","article-title":"Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes","volume":"35","author":"A Sveen","year":"2016","journal-title":"Oncogene"},{"issue":"21","key":"pcbi.1010065.ref032","doi-asserted-by":"crossref","first-page":"11396","DOI":"10.1093\/nar\/gky921","article-title":"Modulation of MKNK2 alternative splicing by splice-switching oligonucleotides as a novel approach for glioblastoma treatment","volume":"46","author":"M Mogilevsky","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"pcbi.1010065.ref033","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-04-3294","article-title":"Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene","volume":"66","author":"DO Watermann","year":"2006","journal-title":"Cancer Res"},{"issue":"1\u20132","key":"pcbi.1010065.ref034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2008.11.001","article-title":"The role of KLF6 and its splice variants in cancer therapy","volume":"12","author":"A DiFeo","year":"2009","journal-title":"Drug Resist Updat"},{"issue":"Suppl 6","key":"pcbi.1010065.ref035","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12864-018-4925-1","article-title":"Characterization of kinase gene expression and splicing profile in prostate cancer with RNA-Seq data","volume":"19","author":"H Feng","year":"2018","journal-title":"BMC Genomics"},{"issue":"5600","key":"pcbi.1010065.ref036","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"G Manning","year":"2002","journal-title":"Science"},{"issue":"2","key":"pcbi.1010065.ref037","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq\u2014a Python framework to work with high-throughput sequencing data","volume":"31","author":"S Anders","year":"2015","journal-title":"Bioinformatics"},{"key":"pcbi.1010065.ref038","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12859-015-0670-5","article-title":"QoRTs: a comprehensive toolset for quality control and data processing of RNA-Seq experiments","volume":"16","author":"SW Hartley","year":"2015","journal-title":"BMC Bioinformatics"},{"key":"pcbi.1010065.ref039","doi-asserted-by":"crossref","first-page":"8971","DOI":"10.1038\/ncomms9971","article-title":"Systematic pan-cancer analysis of tumour purity","volume":"6","author":"D Aran","year":"2015","journal-title":"Nat Commun."},{"issue":"12","key":"pcbi.1010065.ref040","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"MI Love","year":"2014","journal-title":"Genome Biol"},{"issue":"8","key":"pcbi.1010065.ref041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v028.i08","article-title":"Implementing a Class of Permutation Tests: The coin Package","volume":"28","author":"T Hothorn","year":"2008","journal-title":"J Stat Softw."},{"issue":"4","key":"pcbi.1010065.ref042","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1073\/pnas.1814092116","article-title":"The harmonic mean p-value for combining dependent tests","volume":"116","author":"DJ Wilson","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"pcbi.1010065.ref043","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1101\/gr.133744.111","article-title":"Detecting differential usage of exons from RNA-seq data","volume":"22","author":"S Anders","year":"2012","journal-title":"Genome Res"},{"issue":"10","key":"pcbi.1010065.ref044","doi-asserted-by":"crossref","first-page":"a008979","DOI":"10.1101\/cshperspect.a008979","article-title":"Receptor tyrosine kinases in the nucleus","volume":"5","author":"G Carpenter","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4","key":"pcbi.1010065.ref045","first-page":"827","article-title":"Regulation of therapeutic resistance in cancers by receptor tyrosine kinases","volume":"6","author":"MK Chen","year":"2016","journal-title":"Am J Cancer Res"},{"key":"pcbi.1010065.ref046","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.canlet.2018.02.028","article-title":"Nuclear EGFR-PKM2 axis induces cancer stem cell-like characteristics in irradiation-resistant cells","volume":"422","author":"Y Shi","year":"2018","journal-title":"Cancer Lett"},{"issue":"1","key":"pcbi.1010065.ref047","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13046-018-1004-z","article-title":"Systematic analysis of NLMP suggests nuclear localization of RTK\/MET kinases resemble cancer cell clearance","volume":"38","author":"Y Xie","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"pcbi.1010065.ref048","first-page":"2651","article-title":"Activation of EphA4 induced by EphrinA1 exacerbates disruption of the blood-brain barrier following cerebral ischemia-reperfusion via the Rho\/ROCK signaling pathway","volume":"16","author":"F Chen","year":"2018","journal-title":"Exp Ther Med."},{"key":"pcbi.1010065.ref049","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.mcn.2018.07.002","article-title":"EphBs and ephrin-Bs: Trans-synaptic organizers of synapse development and function","volume":"91","author":"NT Henderson","year":"2018","journal-title":"Mol Cell Neurosci"},{"issue":"20","key":"pcbi.1010065.ref050","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1038\/s41388-021-01786-6","article-title":"EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis","volume":"40","author":"L Mao","year":"2021","journal-title":"Oncogene"},{"issue":"9","key":"pcbi.1010065.ref051","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009159","article-title":"Eph receptor signaling and ephrins","volume":"5","author":"EM Lisabeth","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"12","key":"pcbi.1010065.ref052","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/nbt.3682","article-title":"Modeling of RNA-seq fragment sequence bias reduces systematic errors in transcript abundance estimation","volume":"34","author":"MI Love","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"11","key":"pcbi.1010065.ref053","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1101\/gr.233304.117","article-title":"Cell-type-specific eQTL of primary melanocytes facilitates identification of melanoma susceptibility genes","volume":"28","author":"T Zhang","year":"2018","journal-title":"Genome Res"},{"issue":"3","key":"pcbi.1010065.ref054","doi-asserted-by":"crossref","first-page":"F554","DOI":"10.1152\/ajprenal.00062.2011","article-title":"Activity of the Ste20-like kinase, SLK, is enhanced by homodimerization","volume":"301","author":"S Delarosa","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"issue":"5","key":"pcbi.1010065.ref055","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.cell.2008.07.047","article-title":"Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation","volume":"134","author":"P Filippakopoulos","year":"2008","journal-title":"Cell"},{"issue":"5","key":"pcbi.1010065.ref056","first-page":"2625","article-title":"MiR-429-5p attenuates the migration and invasion of malignant melanoma by targeting LIMK1","volume":"24","author":"H Sheng","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"pcbi.1010065.ref057","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1128\/MCB.20.2.684-696.2000","article-title":"Caspase 3 cleavage of the Ste20-related kinase SLK releases and activates an apoptosis-inducing kinase domain and an actin-disassembling region","volume":"20","author":"LA Sabourin","year":"2000","journal-title":"Molecular and cellular biology"},{"issue":"7","key":"pcbi.1010065.ref058","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.clinbiochem.2004.05.003","article-title":"Apoptotic markers in cancer","volume":"37","author":"S Holdenrieder","year":"2004","journal-title":"Clin Biochem"},{"issue":"12","key":"pcbi.1010065.ref059","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/cdd.2016.91","article-title":"Alternative splicing and cell survival: from tissue homeostasis to disease","volume":"23","author":"MP Paronetto","year":"2016","journal-title":"Cell Death Differ"},{"issue":"3","key":"pcbi.1010065.ref060","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/jnci\/80.3.200","article-title":"Evidence for a novel gene associated with low tumor metastatic potential","volume":"80","author":"PS Steeg","year":"1988","journal-title":"J Natl Cancer Inst"},{"key":"pcbi.1010065.ref061","first-page":"4","article-title":"The stress-responsive kinases MAPKAPK2\/MAPKAPK3 activate starvation-induced autophagy through Beclin 1 phosphorylation","author":"Y Wei","year":"2015","journal-title":"Elife"},{"issue":"27","key":"pcbi.1010065.ref062","doi-asserted-by":"crossref","first-page":"20239","DOI":"10.1074\/jbc.C901040199","article-title":"Serine\/Threonine kinases 3pK and MAPK-activated protein kinase 2 interact with the basic helix-loop-helix transcription factor E47 and repress its transcriptional activity","volume":"275","author":"B Neufeld","year":"2000","journal-title":"J Biol Chem"},{"key":"pcbi.1010065.ref063","doi-asserted-by":"crossref","first-page":"105039","DOI":"10.1016\/j.ejps.2019.105039","article-title":"BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation","volume":"138","author":"D Rathod","year":"2019","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"pcbi.1010065.ref064","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s13402-011-0038-4","article-title":"The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival","volume":"34","author":"AG Antonacopoulou","year":"2011","journal-title":"Cell Oncol (Dordr)"},{"issue":"7","key":"pcbi.1010065.ref065","doi-asserted-by":"crossref","first-page":"e1007095","DOI":"10.1371\/journal.pcbi.1007095","article-title":"Aberrant DNA methylation defines isoform usage in cancer, with functional implications","volume":"15","author":"YC Chen","year":"2019","journal-title":"PLoS Comput Biol."},{"issue":"1","key":"pcbi.1010065.ref066","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.molcel.2019.07.005","article-title":"Regulation of Co-transcriptional Pre-mRNA Splicing by m(6)A through the Low-Complexity Protein hnRNPG","volume":"76","author":"KI Zhou","year":"2019","journal-title":"Mol Cell"},{"issue":"31","key":"pcbi.1010065.ref067","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1038\/onc.2009.146","article-title":"The Ste20-like kinase SLK is required for ErbB2-driven breast cancer cell motility","volume":"28","author":"K Roovers","year":"2009","journal-title":"Oncogene"},{"issue":"4","key":"pcbi.1010065.ref068","doi-asserted-by":"crossref","first-page":"e1868","DOI":"10.1371\/journal.pone.0001868","article-title":"FAK\/src-family dependent activation of the Ste20-like kinase SLK is required for microtubule-dependent focal adhesion turnover and cell migration","volume":"3","author":"S Wagner","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"pcbi.1010065.ref069","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/path.4283","article-title":"Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells","volume":"232","author":"Y Fan","year":"2014","journal-title":"J Pathol"},{"key":"pcbi.1010065.ref070","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2407-14-2","article-title":"Mitogen activated protein kinase kinase kinase 3 (MAP3K3\/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis","volume":"14","author":"R Hasan","year":"2014","journal-title":"BMC Cancer"},{"key":"pcbi.1010065.ref071","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.humpath.2015.12.011","article-title":"MAP3K3 overexpression is associated with poor survival in ovarian carcinoma","volume":"50","author":"W Jia","year":"2016","journal-title":"Hum Pathol"},{"issue":"6","key":"pcbi.1010065.ref072","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1172\/JCI91291","article-title":"Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma","volume":"127","author":"M Olvedy","year":"2017","journal-title":"J Clin Invest"},{"issue":"4","key":"pcbi.1010065.ref073","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.chembiol.2012.01.020","article-title":"Small-molecule inhibitors of the c-Fes protein-tyrosine kinase","volume":"19","author":"S Hellwig","year":"2012","journal-title":"Chem Biol"},{"issue":"7","key":"pcbi.1010065.ref074","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/sj.bjc.6605596","article-title":"Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration","volume":"102","author":"G Sonvilla","year":"2010","journal-title":"Br J Cancer"},{"key":"pcbi.1010065.ref075","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1476-4598-12-83","article-title":"FGFR3 has tumor suppressor properties in cells with epithelial phenotype","volume":"12","author":"M Lafitte","year":"2013","journal-title":"Mol Cancer"},{"issue":"Pt 1","key":"pcbi.1010065.ref076","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1042\/bj3430099","article-title":"The N-terminal LIM domain negatively regulates the kinase activity of LIM-kinase 1","volume":"343","author":"K Nagata","year":"1999","journal-title":"Biochem J"},{"issue":"7","key":"pcbi.1010065.ref077","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/1758834017708160","article-title":"Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date","volume":"9","author":"A Boespflug","year":"2017","journal-title":"Ther Adv Med Oncol"},{"issue":"14","key":"pcbi.1010065.ref078","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2012.44.7888","article-title":"Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma","volume":"31","author":"K Trunzer","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"pcbi.1010065.ref079","first-page":"125","article-title":"Angiogenesis in malignant melanoma","volume":"13","author":"M Felcht","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"pcbi.1010065.ref080","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-15-1335","article-title":"Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015\/MK-8628","volume":"6","author":"A Stathis","year":"2016","journal-title":"Cancer Discov"},{"issue":"1","key":"pcbi.1010065.ref081","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1186\/s12864-017-4002-1","article-title":"Evaluation and comparison of computational tools for RNA-seq isoform quantification","volume":"18","author":"C Zhang","year":"2017","journal-title":"BMC Genomics"},{"issue":"1","key":"pcbi.1010065.ref082","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1038\/s41467-019-12990-0","article-title":"A multi-sample approach increases the accuracy of transcript assembly","volume":"10","author":"L Song","year":"2019","journal-title":"Nat Commun"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1010065","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1010065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T13:48:54Z","timestamp":1653486534000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1010065"}},"subtitle":[],"editor":[{"given":"Pau","family":"Creixell","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":82,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1010065","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.08.05.455315","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]}}}